Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Dalpiciclib + AI in Luminal B/HER2- Breast Cancer
NCT05640778Phase 2Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Oct 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dalpiciclib in breast cancer, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Status: unknown.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05640778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05640778.